SLO-BID Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Slo-bid, and when can generic versions of Slo-bid launch?
Slo-bid is a drug marketed by Sanofi Aventis Us and is included in six NDAs.
The generic ingredient in SLO-BID is theophylline. There are thirty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the theophylline profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Slo-bid
A generic version of SLO-BID was approved as theophylline by RHODES PHARMS on September 1st, 1982.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SLO-BID?
- What are the global sales for SLO-BID?
- What is Average Wholesale Price for SLO-BID?
Summary for SLO-BID
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 6 |
| Raw Ingredient (Bulk) Api Vendors: | 171 |
| Patent Applications: | 3,996 |
| DailyMed Link: | SLO-BID at DailyMed |
US Patents and Regulatory Information for SLO-BID
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | SLO-BID | theophylline | CAPSULE, EXTENDED RELEASE;ORAL | 088269-001 | Jan 31, 1985 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sanofi Aventis Us | SLO-BID | theophylline | CAPSULE, EXTENDED RELEASE;ORAL | 089540-001 | May 10, 1989 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sanofi Aventis Us | SLO-BID | theophylline | CAPSULE, EXTENDED RELEASE;ORAL | 089539-001 | May 10, 1989 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
